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Figure 1. Overall survival (OS) and event-free survival (EFS).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S95Methods: Pediatric patients (<21 years old, n¼34) on a
research protocol between 4/2006 and 6/2014 receiving
myeloablative conditioning (FLU/CY/13.2 Gy TBI) with or
without expanded CB HSPC (fresh or cryopreserved) were
included. Duration of initial hospitalization, use of opiate
pain medications (by continuous infusion or PCA), and use of
TPN were determined for each patient. All blood stream in-
fections occurring during initial hospitalization were also
recorded. Statistical comparisons between groups were
made with two-tailed, unpaired t-tests.
Results: 11 patients received expanded CBHSPC in addition to
1-2 unmanipulated CB units while a concurrent cohort of 23
patients received the same conditioning regimen without
expanded cell infusion. The mean time to neutrophil count of
500/mlwas16.5v.22.1days inpatients receivingexpandedcells
or not, respectively (p¼0.026). The mean duration of initial
hospitalization was 43.2 v. 55.6 days (p¼0.05) (Fig. 1), mean
duration for continuous opiate medications 9.7 v. 18.1 days
(p¼0.07), and mean time receiving TPN was 20.7 v. 30.1 days
(p¼0.06) (Fig. 2). Although not statistically signiﬁcant,
bacterial blood stream infections were identiﬁed during their
initial hospitalization in 3 patients receiving expanded CB
HSPC compared to 10 in the standard treatment group.
Conclusions: In addition to reduce time to ANC recovery,
these results suggest that administration of expanded CB
HSPC may signiﬁcantly reduce initial hospitalization and
may also reduce utilization of pain medications and nutri-
tional support in the pediatric population receiving CBT.
Thus, this cellular therapy has the potential to decrease the
risk of morbidity and mortality post-CBT by reducing
regimen related toxicities that directly result from delayed
hematopoietic recovery.93
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HCT for children with severe sickle cell disease have
improved with disease-free survival approaching 95%. As
outcomes have improved, interest in extending HCT to less
severely affected children has increased. However, there re-
mains little published experience in these patients. We
describe the largest multi-institutional retrospective review
of MSD HCT for patients with less severe SCD.
Methods: Patients who received MSD HCT at three centers
(Children’s National Medical Center, Children’s Healthcare of
Atlanta, and Columbia University Medical Center) between
January 2004eJune 2014 were eligible for inclusion in the
analysis. Thosewith severe complications, such as stroke and
recurrent acute chest syndrome, were excluded, using eligi-
bility criteria from a recently completed trial for severe SCD
(clinicaltrials.gov, NCT00968162).
Results: 25 patients (M/F: 13/12) met eligibility. 22 had HbSS
and 3 HbSC. The median age was 5.3 years (1-18.3). 8 patients
had no acute SCD related-complications. The most frequent
complication was vaso-occlusive pain 14/25 (56%) with a life-
timemedian of 1 crisis. 7 patients had splenic sequestration as
the only acute complication. Twenty-four received myeloa-
blative conditioning; 19 received BM, 3 cord blood (CB) and 3
BM + CB. Donor engraftment was achieved in all cases. Mean
peripheral whole blood or myeloid donor chimerismwas 94%
and 89%, at day +100 and +365 respectively. No patients suf-
fered severe regimen-related toxicities and none experienced
seizures, encephalopathy or other neurologic complications.
One patient developed acute GVHD (grade III), which respon-
ded to therapy. None developed chronic GVHD. Of the 17 pa-
tients who are a year or more from transplant, all are off
immune suppression. With a median follow-up of 23 months
(5-130 months) all patients are alive and free of SCD.
Conclusions: HLA MSD HCT for children with less severe
sickle cell appears to be highly effective. Given that nearly all
patients with SCD, regardless of their disease course during
childhood, will suffer serious morbidity as adults and have a
markedly shortened life expectancy, our experience suggests
HCT is appropriate for children with less severe disease.
Prospective studies involving these patients are needed.94
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